Tag Archives: AstraZeneca PLC

Tesaro says it’s for sale, but who can afford it






The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

What’s wrong with Novartis? Actually nothing.






The News: Novartis AG (Basel CHE) has been the subject of widespread and lingering chatter to the effect that its stature among the Big Pharma league players has diminished, and… Read more »

Merck’s Keytruda gets chemo-combo approval for lung cancer; science, stars align for multi-billion medicine






The News: Merck & Co. announced Wednesday (May 10, 2017) that the FDA awarded accelerated approval to Keytruda (pembrolizumab), in combination with Eli Lilly & Co.’s chemotherapy regimen Alimta (pemetrexed)… Read more »

China’s FDA approves AstraZeneca’s lung-cancer drug in new “fast-track” program; European drugmakers beating US to world’s biggest drug market






The News: AstraZeneca PLC (London) has won approval for its lung-cancer pill Tagrisso in China, a key market for the potential blockbuster medicine. Tagrisso is designed to help cancer patients… Read more »

Indy’s Eli Lilly making noise with cancer push; Brickyard neighbor revving its drug-discovery engine






I’ve been to the headquarters of Eli Lilly & Co.–about 15 minutes (or about 5 miles) from the “Brickyard” where the Indianapolis 500 is run each year. The racing is… Read more »

Bristol-Myers plunges, Merck buoyed on cancer-drug news; is it still dash for cash, or race to nowhere?






The News: Bristol-Myers Squibb Co. (New York City) won’t seek accelerated approval of its immunotherapy drug Opdivo for lung cancer, confirming that Merck & Co. (Kenilworth NJ) will have a huge head start… Read more »

Drugs that may shape 2017 and the trends molding new-drug discovery






Here’s a look at the drugs that may shape 2017, compliments of FirstWord Pharma. It’s a list of some of the products I agree are likely to dominate industry news… Read more »

Alexion Suddenly Ousts CEO, CFO; what’s really going on?






Alexion Pharmaceuticals Inc. (New Haven CT), maker of one of the world’s most expensive medicines, announced on Monday (December 12, 2106) its CEO and CFO were departing amid an internal… Read more »

Pfizer misses 3Q views but gets nod for Prevnar from China; Mao would scowl, but not Xi






More than a year after pulling its vaccines out of one of the world’s most challenging but lucrative drug markets, Pfizer has moved back into China with a thumbs up for top-selling… Read more »

Bristol Myers Clobbered as Cancer Drug Disappoints; Rival Merck Unanimous Winner at Medical Conference






New data are likely to prompt doctors to abandon Bristol-Myers Squibb Co.’s (New York City) immunotherapy Opdivo in favor of Merck & Co.’s (Kenilworth NJ) rival Keytruda in a large… Read more »